Patient characteristics | Total |
---|---|
Number of patients | 292 |
Age in years, median (IQR) | 74 (68–80) |
Follow-up time in years, median (IQR) | 3.8 (1.4–6.3) |
Sex, number (%) | |
Male | 222 (76) |
Female | 70 (24) |
Smoking, number (%) | 57 (20) |
ASA score, number (%) | |
1 | 34 (12) |
2 | 174 (60) |
3 | 79 (27) |
4 | 3 (1) |
Clinical local tumour stage, number (%) | |
CIS | 25 (9) |
Ta or T1 | 58 (20) |
T2 | 143 (49) |
T3 | 50 (17) |
T4 | 16 (5) |
Clinical node tumour stage, number (%) | |
N0 | 284 (97) |
N1 | 3 (1) |
N2 or N3 | 5 (2) |
Extent of LND, number (%) | |
None | 51 (18) |
Only enlarged nodes | 19 (7) |
Obturator fossa | 39 (13) |
To the iliac bifurcation | 181 (62) |
To the aortic bifurcation | 2 (1) |
Urinary diversion, number (%) | |
Ileal conduit | 264 (90) |
Neobladder | 7 (2) |
Other | 21 (7) |
Time between CT scan and cystectomy, days, median (IQR) | 48 (33–68) |
Neoadjuvant chemotherapy, number (%) | 26 (9) |
Previous surgery or radiotherapy, number (%) | 72 (25) |
Highest grade 90-day complication, number (%) | |
Grade 0−2 | 74 (25) |
Grade 3 | 48 (16) |
Grade 4 | 4 (1) |
Grade 5 | 4 (1) |
Died during follow-up, number (%) | 160 (55) |
Died during first 2 years of follow-up, number (%) | 95 (33) |